一、公司制定本规划考虑的因素 公司着眼于长远、可持续的发展，综合考虑公司实际情况、发展战略规划 以及行业发展趋势，按照《公司法》《证券法》以及中国证监会、上海证券交易 所有关规定，建立对投资者科学、持续、稳定的回报规划与机制，从而对利润 分配做出制度性安排，以保证利润分配政策的连续性和稳定性。 广州洁特生物过滤股份有限公司 未来三年（2024-2026 年）股东分红回报规划 为进一步完善广州洁特生物过滤股份有限公司（下称"公司"）的利润分配 政策，建立健全科学、持续、稳定的分红机制，增强利润分配的透明度，维护 投资者合法权益，根据中国证监会《上市公司监管指引第 3 号—上市公司现金 分红》和《公司章程》等相关文件规定，结合公司实际情况，特制定公司未来 三年（2024 年-2026 年）股东分红回报规划。 本规划将在符合国家相关法律法规及《公司章程》的前提下，充分重视对 投资者的回报，保持公司的利润分配政策的连续性和稳定性，同时兼顾公司的 长远利益、全体股东的整体利益及公司的可持续发展。公司在利润分配政策的 研究论证和决策过程中，应充分考虑审计委员会成员、公众投资者等方面的意 见。 三、公司未来三年的具体股东回 ...

Overview - The demand for cell culture bags in China is rapidly increasing due to the growth of downstream markets such as biopharmaceuticals, cell therapy, and gene therapy, with a projected demand of 9.723 million units in 2024, a year-on-year increase of 24.53% [1][8] - The market size for cell culture bags is expected to reach 1.05 billion yuan in 2024, reflecting a year-on-year growth of 21.06% [1][8] - Factors such as an aging population and increasing health awareness are driving the demand for biopharmaceutical products, further boosting the cell culture bag market [1][8] Market Policies - A series of supportive policies have been issued in China, including the "14th Five-Year Plan for the Development of the Pharmaceutical Industry" and guidelines for the production quality management of cell therapy products, creating a favorable environment for the development of the cell culture bag industry [6][7] Industry Chain - The upstream of the cell culture bag industry includes suppliers of raw materials like polyethylene and polypropylene, while the midstream involves R&D and production, and the downstream encompasses applications in biopharmaceuticals, cell therapy, and research [7][8] - Biopharmaceuticals account for over 40% of the demand for cell culture bags, primarily used in the production of monoclonal antibodies, recombinant proteins, and vaccines [8] Current Development - The cell culture bag market in China is expanding, with a projected demand of 9.723 million units and a market size of 1.05 billion yuan in 2024, driven by the rapid growth of the biopharmaceutical market [1][8] Competitive Landscape - The market is becoming increasingly competitive, with foreign companies like ThermoFisher Scientific and Corning holding significant market shares due to their advanced technology and product quality [9][10] - Domestic companies such as Guangzhou Jiet Biofilter Co., Ltd. and Wuhan Saikecheng Technology Co., Ltd. are enhancing their R&D efforts and product quality, gradually increasing their market share and competitiveness [10][11] Development Trends - The demand for single-use cell culture bags is expected to continue rising due to their advantages in reducing contamination risks and simplifying operations [12] - There is a growing focus on developing biodegradable or recyclable single-use bags to align with environmental sustainability goals [12] - Domestic companies are expected to narrow the technology gap with foreign products, leading to increased market share and potential international expansion [12]

Company Overview - Jiet Bio is located in Guangzhou Economic and Technological Development Zone, established on April 11, 2001, and listed on January 22, 2020 [1] - The company specializes in cell culture and related products, classified under the pharmaceutical and biological industry, specifically in medical devices and consumables [1] Stock Performance - As of August 22, Jiet Bio's stock price decreased by 2.01%, trading at 19.46 CNY per share, with a total market capitalization of 2.731 billion CNY [1] - Year-to-date, the stock has increased by 52.53%, but has seen a decline of 3.42% over the last five trading days [1] - The stock has experienced a 0.83% increase over the last 20 days and a 23.73% increase over the last 60 days [1] Financial Performance - For the period from January to March 2025, Jiet Bio reported a revenue of 124 million CNY, reflecting a year-on-year growth of 26% [1] - The company has distributed a total of 152 million CNY in dividends since its A-share listing, with 30.06 million CNY distributed over the last three years [1] Shareholder Information - As of March 31, 2025, Jiet Bio had 7,864 shareholders, an increase of 3.79% from the previous period, with an average of 17,837 circulating shares per shareholder, a decrease of 3.65% [1] - Among the top ten circulating shareholders, the Jia Shi Leading Advantage Mixed A fund holds 1.6695 million shares, unchanged from the previous period [2]

Core Viewpoint - The company announces the resignation of its board secretary, Ge Jingbo, due to personal reasons, and he will no longer hold any position within the company [2][3]. Group 1: Resignation Details - Ge Jingbo submitted a written resignation report to the board, which is effective upon delivery to the board [3]. - The company confirms that Ge Jingbo has completed the handover of his responsibilities, and his resignation will not affect the normal operations of the company [3]. Group 2: Impact on the Company - The company will promptly complete the selection of a new board secretary in accordance with relevant regulations and its articles of association [3]. - Until a new board secretary is appointed, the chairman, Yuan Jianhua, will act in this capacity [3]. - Ge Jingbo did not hold any shares in the company during his tenure and was recognized for his diligent work in governance, information disclosure, and investor relations [3].

Core Points - The company, Jiet Bio, announced the resignation of its board secretary, Ge Jingbo, due to personal reasons [1] - Following his resignation, Ge Jingbo will no longer hold any position within the company [1]

Group 1 - The company Jiet Biotech announced the resignation of its board secretary, Ge Jingbo, due to personal reasons, and he will no longer hold any position within the company after his resignation [2] - For the fiscal year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other business segments contribute 4.98% [2]

广州洁特生物过滤股份有限公司（以下简称"公司"）董事会于近日收到公 司董事会秘书葛井波先生的书面辞职报告。葛井波先生因个人原因申请辞去公司 董事会秘书一职，辞职后将不再担任公司任何职务。根据《中华人民共和国公司 法》等法律法规及《公司章程》的有关规定，辞职报告自送达董事会之日起生效。 具体情况如下： | 姓名 | | 离任职务 | | 离任时间 | | | 原定任期到 | | | 是否继续在上 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 期日 | | 离任原因 | 市公司及其控 股子公司任职 | 履行完毕的 公开承诺 | | 葛井波 | 董 | 事 | 会 秘 | 2025 8 | 年 | 月 | 2026 年 9 | 月 | 个人原因 | 否 | 否 | | | 书 | | | 19 日 | | | 14 日 | | | | | | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-049 | | --- | --- | --- | ...

Group 1 - The company, JieTe Bio (688026), announced the resignation of its board secretary, Ge Jingbo, due to personal reasons [1] - Following the resignation, the company’s chairman, Yuan Jianhua, will temporarily assume the responsibilities of the board secretary until a new appointment is made [1]

Core Points - The stock price of Jiet Biotech (688026) closed at 19.77 yuan, down 5.86% as of August 14, 2025 [1] - The company reported a total revenue of 124 million yuan for Q1 2025, representing a year-on-year growth of 26% [1] - Net profit attributable to shareholders reached 16.46 million yuan, up 101.29% year-on-year [1] - The company has a current ratio of 8.034 and a quick ratio of 6.628, indicating strong liquidity [1] Financial Performance - Total revenue for Q1 2025: 1.24 billion yuan, up 26% year-on-year [1] - Net profit: 16.46 million yuan, up 101.29% year-on-year [1] - Non-recurring net profit: 15.65 million yuan, up 269.23% year-on-year [1] - Asset-liability ratio: 28.76% [1] Company Overview - Jiet Biotech was established in 2001 and is located in Guangzhou [2] - The company focuses on research and experimental development [2] - Registered capital: 1.403 billion yuan, paid-in capital: 40 million yuan [2] - The legal representative is Yuan Jianhua [2] Investment and Intellectual Property - The company has invested in 14 enterprises and participated in 182 bidding projects [2] - It holds 79 trademark registrations and 266 patents [2] - The company has obtained 67 administrative licenses [2]

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock price performance [2][7]. Group 1: Convertible Bond Details - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB [3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and further adjusted to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025 [4]. - The downward adjustment clause is triggered when the stock price is below 85% of the conversion price for at least 15 out of 30 consecutive trading days [5]. Group 2: Board Decision - The board of directors convened on August 1, 2025, and unanimously agreed not to adjust the conversion price, with all related directors abstaining from the vote [8][9]. - The decision will remain in effect for three months, until November 1, 2025, during which time the company will not propose any downward adjustment even if the clause is triggered again [7][9].